BR112023019999A2 - Métodos para depletar seletivamente fragmentos não desejáveis de bibliotecas amplificadas de dna ou cdna mediante o uso de um ou mais oligonucleotídeos bloqueadores e kits para a preparação de biblioteca baseada em rna-seq - Google Patents

Métodos para depletar seletivamente fragmentos não desejáveis de bibliotecas amplificadas de dna ou cdna mediante o uso de um ou mais oligonucleotídeos bloqueadores e kits para a preparação de biblioteca baseada em rna-seq

Info

Publication number
BR112023019999A2
BR112023019999A2 BR112023019999A BR112023019999A BR112023019999A2 BR 112023019999 A2 BR112023019999 A2 BR 112023019999A2 BR 112023019999 A BR112023019999 A BR 112023019999A BR 112023019999 A BR112023019999 A BR 112023019999A BR 112023019999 A2 BR112023019999 A2 BR 112023019999A2
Authority
BR
Brazil
Prior art keywords
kits
methods
rna
seq
blocking oligonucleotides
Prior art date
Application number
BR112023019999A
Other languages
English (en)
Inventor
Angelica Barr
Colin Brown
Samantha Snow
Sarah SHULTZABERGER
m gross Stephen
Original Assignee
Illumina Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Illumina Inc filed Critical Illumina Inc
Publication of BR112023019999A2 publication Critical patent/BR112023019999A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/113—Modifications characterised by incorporating modified backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/117—Modifications characterised by incorporating modified base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/186—Modifications characterised by incorporating a non-extendable or blocking moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/163—Reactions characterised by the reaction format or use of a specific feature the purpose or use of blocking probe

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

métodos para depletar seletivamente fragmentos não desejáveis de bibliotecas amplificadas de dna ou cdna mediante o uso de um ou mais oligonucleotídeos bloqueadores e kits para a preparação de biblioteca baseada em rna-seq. a revelação se refere a métodos, composições e kits para a depleção seletiva de fragmentos não desejáveis de bibliotecas amplificadas com o uso de oligonucleotídeos bloqueadores.
BR112023019999A 2021-03-31 2022-03-30 Métodos para depletar seletivamente fragmentos não desejáveis de bibliotecas amplificadas de dna ou cdna mediante o uso de um ou mais oligonucleotídeos bloqueadores e kits para a preparação de biblioteca baseada em rna-seq BR112023019999A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163169185P 2021-03-31 2021-03-31
PCT/US2022/022663 WO2022212589A1 (en) 2021-03-31 2022-03-30 Blocking oligonucleotides for the selective depletion of non-desirable fragments from amplified libraries

Publications (1)

Publication Number Publication Date
BR112023019999A2 true BR112023019999A2 (pt) 2023-11-14

Family

ID=81346581

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019999A BR112023019999A2 (pt) 2021-03-31 2022-03-30 Métodos para depletar seletivamente fragmentos não desejáveis de bibliotecas amplificadas de dna ou cdna mediante o uso de um ou mais oligonucleotídeos bloqueadores e kits para a preparação de biblioteca baseada em rna-seq

Country Status (11)

Country Link
US (1) US20240191288A1 (pt)
EP (1) EP4314335A1 (pt)
JP (1) JP2024512463A (pt)
KR (1) KR20230163386A (pt)
CN (1) CN117098855A (pt)
AU (1) AU2022252302A1 (pt)
BR (1) BR112023019999A2 (pt)
CA (1) CA3213037A1 (pt)
IL (1) IL306060A (pt)
MX (1) MX2023011523A (pt)
WO (1) WO2022212589A1 (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5962271A (en) 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
US5849497A (en) * 1997-04-03 1998-12-15 The Research Foundation Of State University Of New York Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker
US6391592B1 (en) * 2000-12-14 2002-05-21 Affymetrix, Inc. Blocker-aided target amplification of nucleic acids
JP5073967B2 (ja) 2006-05-30 2012-11-14 株式会社日立製作所 単一細胞の遺伝子発現定量方法
WO2013191775A2 (en) * 2012-06-18 2013-12-27 Nugen Technologies, Inc. Compositions and methods for negative selection of non-desired nucleic acid sequences
US20140274729A1 (en) * 2013-03-15 2014-09-18 Nugen Technologies, Inc. Methods, compositions and kits for generation of stranded rna or dna libraries
WO2017142989A1 (en) * 2016-02-17 2017-08-24 Admera Health LLC Nucleic acid preparation and analysis
US11319583B2 (en) * 2017-02-01 2022-05-03 Becton, Dickinson And Company Selective amplification using blocking oligonucleotides
US11028436B2 (en) * 2017-05-08 2021-06-08 Illumina, Inc. Universal short adapters for indexing of polynucleotide samples

Also Published As

Publication number Publication date
EP4314335A1 (en) 2024-02-07
MX2023011523A (es) 2023-10-06
CA3213037A1 (en) 2022-10-06
AU2022252302A1 (en) 2023-09-14
CN117098855A (zh) 2023-11-21
US20240191288A1 (en) 2024-06-13
KR20230163386A (ko) 2023-11-30
JP2024512463A (ja) 2024-03-19
IL306060A (en) 2023-11-01
WO2022212589A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
NO20081907L (no) Forsinkede hydrokarbongelfornettere og fremgangsmater for fremstilling og anvendelse av disse
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
WO2020096631A3 (en) Compositions, methods and systems for protein corona analysis and uses thereof
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CL2021000028A1 (es) Anticuerpo multiespecifico (divisional de solicitud 937-2020).
BRPI0617162B8 (pt) compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
BRPI0616630B8 (pt) compostos de pirazol substituídos
BRPI0815564B8 (pt) anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
ECSP099071A (es) Agonistas de ep2
CL2009000559A1 (es) Composicion farmaceutica que comprende trastuzumab-mcc-dm1 y un agente quimioterapeutico seleccionado de un anticuerpo inhibidor de la dimerizacion de her2, un anticuerpo anti-vegf, 5-fu, carboplatino, lapatinib, abt-869, docetaxel, gdc-0941 y gne-390; y su uso para el tratamiento de un trastorno hiperproliferante.
MX2022004937A (es) Inhibidores de las cinasas raf.
BRPI0517887A (pt) combinações de inibidores de jaks
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
BRPI0903359B8 (pt) composição farmacêutica de metformina, ácido acetilsalicílico e composto de serotonina para o tratamento do câncer
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
BR112022003357A2 (pt) Compostos heterocíclicos
BR112018076528A2 (pt) composições e métodos para diagnosticar cânceres de pulmão usando perfis de expressão gênica
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso